Abstract
Objectives
Yttrium-90 radioembolization is a hepatic intra-arterial-based therapy using glass- or resin-based microspheres as carriers to deliver high-dose radiation to tumors to maximize dose while minimizing collateral damage. This study aimed to compare the safety and efficacy of glass (TheraSphere) versus resin (Selective Internal Radiation Spheres, SIR-Spheres) Y-90 in the treatment of intrahepatic metastatic disease.
Methods
A review of a prospectively collected, institutional review board-approved database was conducted to identify patients who underwent Y-90 therapy, excluding those with hepatocellular carcinoma (HCC).
Results
Of 119 patients, 79 received SIR-Spheres and 40 received TheraSphere therapy. For intrahepatic cholangiocarcinoma, mean survival was 10.6 months in the SIR-Spheres group compared to 29.2 months in the TheraSphere group (log-rank 0.05). In colorectal cancer (CRC), mean survival was 16.3 months for SIR-Spheres therapy and 26.8 for TheraSphere therapy (log-rank 0.097). There were no documented severe (grade 3) side effects in the TheraSphere group compared to 14 % of patients who experienced side effects in the SIR-Spheres group.
Conclusions
TheraSphere microsphere appears superior to SIR-Spheres in treating non-HCC intrahepatic malignancy. However, patient selection and better multi-disciplinary care may play a role in these differences. Continued studies in combination therapies for all hepatic malignancies is critical to the long-term success and sustainability of Y-90 therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Breedis C, Young G (1954) The blood supply of neoplasms in the liver. Am J Pathol 30(5):969–977
Kennedy AS et al (2006) Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 65(2):412–425
Lewandowski RJ, Salem R (2006) Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver. Semin Intervent Radiol 23(1):64–72
Kulik LM et al (2006) Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94(7):572–586
Salem R, Thurston KG (2006) Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol 17(8):1251–1278
Lau WY et al (2004) Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg 240(2):299–305
Kim DY et al (2006) Successful embolization of hepatocelluar carcinoma with yttrium-90 glass microspheres prior to liver transplantation. J Gastrointest Surg 10(3):413–416
Al-Adra DP et al (2015) Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol 41(1):120–127
Coldwell D, K.A. Treatment of nodular cholangiocarcinoma with yttrium-90 microspheres. In World Congress on Gastrointestinal Cancer 2006. Barcelona, Spain.
Zhang Z et al (2013) Comparison of therapeutic response using RECIST criteria: Y-90 SIR-Spheres and TheraSphere treatment of unresectable hepatocellular carcinoma. J NUCL MED MEETING ABSTRACTS 54(2_MeetingAbstracts):224
Zhang Z et al (2012) Comparison study of the treatment of unresectable hepatocellular carcinoma with Y-90 SIR-Spheres and Y-90 TheraSphere. J Nucl Med 53(supplement 1):1201
Woodall CE et al (2009) Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis? J Am Coll Surg 208(3):375–382
Kennedy AS et al (2006) Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. IntJRadiatOncolBiolPhys 65(2):412–425
Choi H et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25(13):1753–1759
Llovet JM et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100(10):698–711
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The work was supported by the Division of Surgical Oncology at the University of Louisville School of Medicine.
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Burnett, N.P., Akinwande, O., Scoggins, C.R. et al. Comparison of Yttrium-90 therapy for unresectable liver metastasis: glass versus biocompatible resin microspheres. J Radiat Oncol 6, 101–108 (2017). https://doi.org/10.1007/s13566-016-0282-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13566-016-0282-3